11/22/2010

Bristol-Myers Squibb and Sanofi-Aventis have obtained the European Medicines Agency's endorsement to use anti-clotting drug Plavix for the prevention of thromboembolic and atherothrombotic events in certain adults with atrial fibrillation.

Full Story:
Reuters

Related Summaries